Ireland-based Endo International plc (NASDAQ: ENDP) has announced a licensing deal between its subsidiary Endo Ventures Ltd (EVL) and Taiwan Liposome Company Ltd (TLC). The agreement centers on TLC’s TLC599, a novel injectable nanomedicine compound currently in Phase III development for osteoarthritis (OA) knee pain.
Deal Terms and Financials
Under the terms of the deal, TLC will continue to oversee product development, while Endo will hold regulatory and commercial rights in the United States. Endo is committing USD 30 million upfront, with the potential for up to USD 110 million in development and manufacturing milestone payments. Additionally, there will be undisclosed commercial milestone payments and royalties on future sales payable to TLC.
TLC599: Innovative Nanomedicine for Chronic Knee OA Pain
TLC599 is an extended and controlled-release liposomal formulation of dexamethasone designed to address chronic knee OA pain. The drug aims to improve upon current intraarticular anti-inflammatory treatments for OA by reducing toxicity and the destruction of cartilage filler proteins. The ongoing Phase III EXCELLENCE trial, led by TLC, is evaluating the safety and efficacy of both single and repeated doses of TLC599 and is nearing completion at the time of the deal.-Fineline Info & Tech
